Jankowski, T., Sezer, A., Kowal-Rosinska, M., Müller, V., Csoszi, T., Nagy, T., Ramlau, R., Soter, S., Volovat, C. D., Amurariti, F., Sirbu, D. E., Bobora, R., Mender, I., Girotti, R., Mitsunaga, M., Tudos, O., Failor, M., Vitoc, V., Gryaznov, S., Zaporojan, V. (2026). A phase 3 study of ateganosine (THIO; 6-thio-2'-deoxyguanosine) sequenced with immune checkpoint inhibitor (ICI) versus standard-of-care chemotherapy in ICI-resistant advanced NSCLC: THIO-104 trial in progress.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps8672